Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

This lecture was part of a CME accredited symposium; SGLT2 inhibition, diabetes and CVD: Where does this fit in CV risk management? held at ESc 2016 in Rome

Video navigation menu

Incidence of diabetes 00:06
Multifactorial prevention of CV morbidity and mortality 02:51
Glucose-lowering medication – GLP-1 inhibitor liraglutide in the LEADER trial 07:56
Glucose-lowering medication – SGLT2 inhibitor empagliflozin in the EMPA-REG OUTCOME trial 08:41

Educational information

Educational objectives of this symposium were to:

Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes-
Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients

CME accreditation

This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

Professor John Deanfield, MD - Professor of Cardiology - Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom

Funding

Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Also watch lecture: Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift? by prof John McMurray, MD University of Glasgow United Kingdom Also watch lecture: Overview of SGLT-2 inhibitors in T2DM management: current position & future promise by prof Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.